|
|
 |
|
Viewing report
|
|
|
|
Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, May 2011, Pages: 78
Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global RVO market. The report identifies the key trends shaping and driving the global RVO market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global RVO sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData valued the Retinal Vein Occlusion (RVO) therapeutics market in 2010 at $496m, indicating a growth rate of 29.25% between 2005 and 2010. Until the market entry of Lucentis (ranibizumab) in 2006, the RVO therapeutics market was growing at a lower rate. After the entry of Lucentis, the market registered a growth rate of 40.13% between 2006 and 2007. Up until now, Lucentis and Ozurdex have been the only approved drugs for the treatment of RVO. The late-stage clinical development pipeline consists of 50% first-in-class and 50% me-too drugs that are effective and safe for RVO patients. Once these drugs enter the market, the market will grow further at a significant rate. Therefore, GlobalData estimates that the RVO therapeutics market in 2017 will be $1.4 billion, indicating a Compound Annual Growth Rate (CAGR) of 16.08% between 2010 and 2017
Scope
The report provides information on the key drivers and challenges of the retinal vein occlusion therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) retinal vein occlusion therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as VEGF inhibitors, HMG CoA reductase inhibitors, Glucocorticoid receptor agonists, and kallikrein inhibitors.
- Analysis of the current and future competition in the seven key countries retinal vein occlusion market. Key market players covered are Allergan, Inc., Alimera Sciences, Icon Biosciences, and Regeneron Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the retinal vein occlusion therapeutics market.
- Analysis of key recent licensing and partnership agreements in retinal vein occlusion market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global retinal vein occlusion market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global retinal vein occlusion market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global retinal vein occlusion market landscape? – Identify, understand and capitalize.
|
|
|
|
